Breaking News

The American Association for Cancer Research annual meeting wrapped up today in Chicago. Below are selected business briefs from the conference.

MedTek21's software is designed to continuously analyze patient records to provide real-time personalized medication reports to physicians.

The national PROFYLE study seeks to sequence tumor and matched normal samples from children and young adults with relapsed or treatment-resistant cancer.

The deals cover the company's synthetic DNA and next-generation sequencing products, including its newly launched target enrichment line.

Isoma, which launched last year, will use the funds to develop and clinically validate a molecular test for stratifying glioblastoma patients.

Miami-based Nicklaus will send patient blood samples to Rady Children's in San Diego for WGS, bioinformatics analysis, and initial clinical interpretation.

The firms will work to accelerate the adoption of PierianDx's genomics platform for translating data into patient-specific diagnoses and treatments.

The team's approach discovered cell-essential and human embryonic stem cell-essential genes in karyotypically stable human pluripotent stem cells

Investigators from several centers outlined tumor features, treatment strategies, and clinical trial classifications coming from tumor-germline clinical sequencing programs.

The researchers used UK Biobank data to identify loci linked to depression and identify gene sets involved in excitatory neurotransmission and mechanosensory behavior.

The deal is the first for Hong Kong-based Prenetics and marks its foray into the consumer genomics space.

Cincinnati Children's Hospital Medical Center researchers found that disease risk loci overlap with transcription factor binding sites.

The international team of researchers uncovered more than 100 loci, mostly novel, through their analysis of a cohort of nearly 300,000 people.

The company will use the funding to advance the commercialization of its proprietary liquid biopsy technology.

The firm said that its Cobas CT/NG real-time PCR assay is the first available in the US for the testing of sexually transmitted infections on its 6800 and 8800 systems.

Conducting studies on Latina and African-American women produces population-specific insights on the genetics of the disease that aren't possible to glean in European-heavy GWAS.

Plenary session Chairwoman Elaine Mardis said the presentations made it clear how great the need is for interdisciplinary science as data becomes ever more complex.

The companies plan to commercialize MIODx's immune sequencing technology for diagnostic purposes.

The test is designed to identify a tumor's tissue of origin by assessing 2,000 individual genes and covers 15 common tumor types.

A Color Genomics collaborator reported that nearly half of first-degree relatives who were invited for reduced-cost testing in cancer-related genes opted to participate.

The companies plan to develop a broad NGS panel to analyze all known biomarkers for cancer drugs, including tumor mutation burden and microsatellite instability.

HudsonAlpha researchers analyzed the genomes of parents whose children were in a study of developmental delay and intellectual disability for secondary findings.

Pages

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.